Riskpilot← Back to searchSign inGet full accessNordic Pharma Lab ApS
APSActiveCVR 39161672Slotsmarken 12, 1. thManufacture of pharmaceutical preparations · NACE 2120Est. 2017— employees
Revenue 2024
DKK -19K
+1% vs 2023
EBITDA margin
100.0%
-1% vs 2023
Equity ratio
-6045.0%
Financial strength
Net profit 2024
DKK -31K
-8% vs 2023
| Revenue | DKK -19K | +1% |
| EBITDA | DKK -19K | -1% |
| Net profit | DKK -31K | -8% |
| Total assets | DKK 5K | +26% |
| Equity | DKK -319K | -11% |
| Employees | — | — |
Legal name
Nordic Pharma Lab ApS
CVR number
39161672
Legal form
Anpartsselskab
NACE code
2120 · Manufacture of pharmaceutical preparations
Founded
10. december 2017
Share capital
DKK 100.000
Employees
—
VAT registered
Yes
Audit selected
Yes
Last report
2024-12-31
Financial year
January – December
Signatory rights
Selskabet tegnes af en direktør
Company purpose
Selskabets formål er at udvikle repositionerede lægemidler samt dermed beslægtede aktiviteter.
Address
Slotsmarken 12, 1. th
Risika for professionals
Risika provides regulated workflow tools for finance, procurement and compliance teams that need monitoring, alerts and an API.
| Item | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|---|---|
| Revenue | -11 | -12 | 0 | -106 | -24 | -19 | -19 |
| Staff expenses | -0 | -0 | -0 | -0 | -0 | -0 | -0 |
| EBITDA | -11 | -12 | -41 | -106 | -24 | -19 | -19 |
| Depreciation & amort. | -0 | -0 | -0 | -178 | -0 | -0 | -0 |
| EBIT | -11 | -12 | -41 | -284 | -24 | -19 | -19 |
| Net financials | 0 | -0 | -0 | -0 | -9 | -10 | -12 |
| Profit before tax | -11 | -12 | -41 | -284 | -33 | -29 | -31 |
| Tax | -0 | -0 | -21 | -1 | -0 | -1 | -0 |
| Net profit | -11 | -12 | -20 | -283 | -33 | -28 | -31 |
| Item | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|---|---|
| Total assets | 96 | 93 | 212 | 30 | 8 | 4 | 5 |
| Equity | 89 | 77 | 57 | -226 | -260 | -288 | -319 |
| Long-term debt | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Short-term debt | 8 | 16 | 153 | 256 | 267 | 292 | 324 |
| Total debt | 8 | 16 | 153 | 256 | 267 | 292 | 324 |
EBITDA margin
-1891800.0%
This company
15.8%
Market median
-11973518% vs market
20182024
Equity ratio
-6045.0%
This company
38.2%
Market median
-15925% vs market
20182024
Return on equity
-3057300.0%
This company
18.4%
Market median
-16615861% vs market
20182024
Net profit margin
-3057300.0%
This company
8.1%
Market median
-37744544% vs market
20182024
Asset turnover
-3.59×
This company
1.12×
Market median
-421% vs market
20182024
Debt / equity
1.02×
This company
0.62×
Market median
-65% vs market
20182024
- Annual report 2024Filed via CVR / Virk · Period 2024-01-01 – 2024-12-31
- Annual report 2023Filed via CVR / Virk · Period 2023-01-01 – 2023-12-31
- Annual report 2022Filed via CVR / Virk · Period 2022-01-01 – 2022-12-31
- Annual report 2021Filed via CVR / Virk · Period 2021-01-01 – 2021-12-31
- Annual report 2020Filed via CVR / Virk · Period 2020-01-01 – 2020-12-31
- Annual report 2019Filed via CVR / Virk · Period 2019-01-01 – 2019-12-31
- Annual report 2018Filed via CVR / Virk · Period 2017-12-10 – 2018-12-31
| Name | Role | Member since | Age | Other directorships |
|---|---|---|---|---|
TB Management | Management | 2017 | — | — |
PA Management | Management | 2017 | — | — |
No data on file.
| Shareholder | Type | Ownership | Votes | Since |
|---|---|---|---|---|
FINANSMANAGEMENT ApS | Company | 50.0% | 50.0% | 2022 |
Beier Holding ApS | Company | 20.0% | 20.0% | 2020 |
TT 1919 ApS | Company | 5.0% | 5.0% | 2020 |
VULKAN INVEST ApS | Company | 5.0% | 5.0% | 2020 |
PM Group Holding ApS | Company | 10.0% | 10.0% | 2020 |
Beneficial ownership (UBO) data access is restricted in Denmark as of September 2025 per the EU 6th AML Directive. Learn more.
TT 1919 ApS
Nordic Pharma Lab ApS Board members of Nordic Pharma Lab ApS also hold positions in 0 other companies.
| Person | Role here | Other companies |
|---|---|---|
| Torsten Bjørn | Management | 0 companies |
| Peter Andreas Stakemann | Management | 0 companies |